Indications and applicable groups of acotinib

Acalabrutinib is a targeted therapy drug that is a Bruton's tyrosine kinase (BTK) inhibitor and is mainly used to treat certain types of blood cancers, especially B cell malignancies. By inhibiting BTK, acotinib blocks the signaling of B cells, thereby inhibiting the growth and spread of cancer cells. It is approved to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and other diseases.

Acotinib is indicated for patients with chronic lymphocytic leukemia (CLL), especially those who have not had a complete response to prior therapy. CLL is a common adult leukemia. The use of acotinib can effectively inhibit the spread of tumor cells and significantly improve the survival and quality of life of patients. Acotinib provides an important treatment option for some patients who are unable to receive other traditional treatments.

In addition toCLL, acotinib is also suitable for patients with small lymphocytic lymphoma (SLL). SLL is a B cell lymphoma that is very similar to CLL, and acotinib plays a similar role in the treatment of SLL by targeting BTK. For these patients, acotinib can effectively control the disease and delay disease progression. Especially when other treatment options are ineffective, acotinib provides patients with a new treatment hope.

In general, acotinib is mainly suitable for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Especially for patients who have received other treatments but have relapsed or failed to achieve expected results, acotinib provides an effective treatment option. In clinical practice, doctors will decide whether to use acotinib as part of the treatment plan based on the patient's specific condition, previous treatment history and individual needs.

Reference materials:https://www.calquence.com/